182 results on '"Thaker, Premal H"'
Search Results
2. Characterizing the genomic landscape through the lens of FOLR1 status in low and high grade serous ovarian carcinoma
3. Quality of life and survivorship in patients with low-grade ovarian cancer
4. A toolkit for a modern gynecologic oncology tissue bank
5. Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016
6. Molecular profiling of gestational trophoblastic neoplasia: Identifying therapeutic targets
7. Rural-urban disparities in psychosocial functioning in epithelial ovarian cancer patients
8. TP53 mutation and abnormal p53 expression in endometrial cancer: Associations with race and outcomes
9. Differential outcomes and immune checkpoint inhibitor response among endometrial cancer patients with MLH1 hypermethylation versus MLH1 “Lynch-like” mismatch repair gene mutation
10. A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283
11. HER2+ endometrioid endometrial cancer possesses distinct molecular and immunologic features associated with a more active immune microenvironment and worse prognosis
12. GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group study
13. High visceral fat to subcutaneous fat ratios portend a poor prognosis in patients with advanced endometrial cancer
14. Management and prognosis of cervical cancer patients treated with definitive radiation therapy who have partial metabolic response on post-therapy positron emission tomography
15. Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer
16. Rural residence is related to shorter survival in epithelial ovarian cancer patients
17. Text-message-based behavioral weight loss for endometrial cancer survivors with obesity: A randomized controlled trial
18. Uterine carcinosarcomas: From pathology to practice
19. A deficit-accumulation frailty index predicts survival outcomes in patients with gynecologic malignancy
20. Impact of employment and insurance status on distress in gynecologic oncology patients
21. A fellow-run clinic achieves similar patient outcomes as faculty clinics: A safe and feasible model for gynecologic oncology fellow education
22. FIGO 2018 staging criteria for cervical cancer: Impact on stage migration and survival
23. Is hormonal therapy after risk-reducing salpingo-oophorectomy associated with an increased risk of malignancy in pathogenic variant carriers?
24. Modified frailty index is predictive of wound complications in obese patients undergoing gynecologic surgery via a midline vertical incision
25. Low rates of cascade genetic testing among families with hereditary gynecologic cancer: An opportunity to improve cancer prevention
26. Recurrence, death, and secondary malignancy after ovarian conservation for young women with early-stage low-grade endometrial cancer
27. Risk of cervical and vaginal dysplasia after surgery for vulvar intraepithelial neoplasia or cancer: A 6 year follow-up study
28. Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression
29. Continuous epidural infusion in gynecologic oncology patients undergoing exploratory laparotomy: The new standard for decreased postoperative pain and opioid use
30. Association between body mass index and surgical menopausal symptoms in patients with early stage endometrial cancer
31. Novel treatment options in platinum-sensitive recurrent ovarian cancer: A review
32. SQ1274, a novel microtubule inhibitor, inhibits ovarian and uterine cancer cell growth
33. Benefit of combination chemotherapy and radiation stratified by grade of stage IIIC endometrial cancer
34. A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study
35. The effect of a multidisciplinary palliative care initiative on end of life care in gynecologic oncology patients
36. Identification of molecular targets in vulvar cancers
37. A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study
38. Stress and burnout among gynecologic oncologists: A Society of Gynecologic Oncology Evidence-based Review and Recommendations
39. Clinicopathologic characteristics and survival of patients with gynecologic malignancies metastatic to the brain
40. Feeling powerless: Locus of control as a potential target for supportive care interventions to increase quality of life and decrease anxiety in ovarian cancer patients
41. A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): An NRG Oncology/Gynecologic Oncology Group study
42. A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study
43. Impact of an immunohistochemistry-based universal screening protocol for Lynch syndrome in endometrial cancer on genetic counseling and testing
44. A phase II trial of a surgical protocol to decrease the incidence of wound complications in obese gynecologic oncology patients
45. A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: A Gynecologic Oncology Group study
46. Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer
47. Non-cancer life stressors contribute to impaired quality of life in ovarian cancer patients
48. Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer
49. Intestinal perforation in gynecologic oncology: Do all patients benefit from surgical management?
50. Low yield of residual vulvar carcinoma and dysplasia upon re-excision for close or positive margins
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.